Paul Tudor Jones's REGN Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 37,604 shares of Regeneron Pharmaceuticals, Inc. (REGN) worth $28.51 M, representing 0.04% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 41 quarters.
Based on 13F filings since 2013, Paul Tudor Jones has maintained a long-term strategic position in REGN, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2025, adding 97,523 shares. Largest reduction occurred in Q3 2025, reducing 84,550 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Regeneron Pharmaceuticals (REGN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Regeneron Pharmaceuticals (REGN) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2026 | +37,604 | New Buy | 37,604 | $758.27 |
| Q3 2025 | -84,550 | Sold Out | 0 | $0.00 |
| Q2 2025 | -41,543 | Reduce 32.95% | 84,550 | $525.00 |
| Q1 2025 | +97,523 | Add 341.35% | 126,093 | $634.23 |
| Q4 2024 | -9,081 | Reduce 24.12% | 28,570 | $712.33 |
| Q3 2024 | +37,651 | New Buy | 37,651 | $1051.24 |
| Q4 2023 | -5,799 | Sold Out | 0 | $0.00 |
| Q3 2023 | -7,847 | Reduce 57.50% | 5,799 | $822.96 |
| Q2 2023 | +10,574 | Add 344.21% | 13,646 | $718.54 |
| Q1 2023 | -542 | Reduce 15.00% | 3,072 | $0.82 |
| Q4 2022 | +3,614 | New Buy | 3,614 | $0.72 |
| Q3 2022 | -1,690 | Sold Out | 0 | $0.00 |
| Q2 2022 | +1,690 | New Buy | 1,690 | $591.12 |
| Q3 2021 | -1,591 | Sold Out | 0 | $0.00 |
| Q2 2021 | +1,591 | New Buy | 1,591 | $558.77 |
| Q2 2020 | -2,426 | Sold Out | 0 | $0.00 |
| Q1 2020 | -2,670 | Reduce 52.39% | 2,426 | $488.46 |
| Q4 2019 | +5,096 | New Buy | 5,096 | $375.39 |
| Q3 2019 | -785 | Sold Out | 0 | $0.00 |
| Q2 2019 | -1,650 | Reduce 67.76% | 785 | $313.38 |
| Q1 2019 | +2,435 | New Buy | 2,435 | $410.68 |
| Q4 2018 | -1,278 | Sold Out | 0 | $0.00 |
| Q3 2018 | -7,754 | Reduce 85.85% | 1,278 | $403.76 |
| Q2 2018 | +9,032 | New Buy | 9,032 | $345.00 |
| Q1 2018 | -4,017 | Sold Out | 0 | $0.00 |
| Q4 2017 | +4,017 | New Buy | 4,017 | $375.90 |
| Q2 2017 | -600 | Sold Out | 0 | $0.00 |
| Q1 2017 | +600 | New Buy | 600 | $388.33 |
| Q4 2016 | -4,608 | Sold Out | 0 | $0.00 |
| Q3 2016 | +1,652 | Add 55.89% | 4,608 | $402.13 |
| Q2 2016 | +2,956 | New Buy | 2,956 | $349.12 |
| Q1 2016 | -700 | Sold Out | 0 | $0.00 |
| Q4 2015 | -390 | Reduce 35.78% | 700 | $542.86 |
| Q3 2015 | +690 | Add 172.50% | 1,090 | $465.14 |
| Q2 2015 | +400 | New Buy | 400 | $510.00 |
| Q4 2014 | -2,499 | Sold Out | 0 | $0.00 |
| Q3 2014 | +2,499 | New Buy | 2,499 | $360.54 |
| Q2 2014 | -893 | Sold Out | 0 | $0.00 |
| Q1 2014 | +893 | New Buy | 893 | $300.11 |
| Q3 2013 | -1,600 | Sold Out | 0 | $0.00 |
| Q2 2013 | +1,600 | Add 0.00% | 1,600 | $225.00 |
Paul Tudor Jones's Regeneron Pharmaceuticals Investment FAQs
Paul Tudor Jones first purchased Regeneron Pharmaceuticals, Inc. (REGN) in Q2 2013, acquiring 1,600 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Regeneron Pharmaceuticals, Inc. (REGN) for 41 quarters since Q2 2013.
Paul Tudor Jones's largest addition to Regeneron Pharmaceuticals, Inc. (REGN) was in Q1 2025, adding 126,093 shares worth $79.97 M.
According to the latest 13F filing for Q3 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 37,604 shares of Regeneron Pharmaceuticals, Inc. (REGN), valued at approximately $28.51 M.
As of the Q3 2026 filing, Regeneron Pharmaceuticals, Inc. (REGN) represents approximately 0.04% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Regeneron Pharmaceuticals, Inc. (REGN) was 126,093 shares, as reported at the end of Q1 2025.